Adipokines, myokines and cytokines in endometrial cancer patients: relations to obesity phenotype of excessive body mass and features of the tumor

Aim. To study serum content of a number of known adipokines, myokines and cytokines and compare obtained data with overweight phenotype and characteristics of tumor in untreated patients with endometrial cancer (EC)

Materials and methods. The study included 88 patients with a mean age 60.08±0.67 years and a mean body mass index (BMI) 32.90±0.83. Patients were subjected to anthropometry and analysis of laboratory parameters, including serum level of leptin, adiponectin, omentin, prefilin (Pref-1), myostatin, irisin, IL-6 as well as insulinemia and insulin resistance index (HOMA-IR). On the basis of combination of anthropometric and laboratory data patients with overweight (BMI >25.0) were subdivided into the groups with "standard" (S) and conditionally "metabolically healthy" (MH) phenotype.

Results. Levels of leptin, insulin and adiponectin in the serum of patients with EC are associated with BMI value and demonstrate significant differences between S and MH groups. Levels of prefilin, myostatin, and IL-6 are not associated with an increase in BMI, but are also different in patients with S and MH phenotype of overweight.For levels oа irisin, omentin, and TNF-alphathere is no peculiar dependence both, the BMI, and of belonging to a group with S or MH phenotype. Omentin level in the serum is associated with less favorable tumor differentiation (MH group), while IL-6 level – with a more advanced stage of the tumor (all patients and group S).

Conclusion. Adipokines, myokines and cytokines circulating in blood of EC patients vary in their connections with BMI or with "standard" or "metabolically healthy" phenotype of its excess. They vary also in relation to EC features, which in sum may have practical importance.

leptin, adiponectin, omentin, prefilifin (Pref-1), myostatin, irisin, tumor necrosis factor-alpha, interleukin-6, excessive body mass phenotype, endometrial carcinoma

1. Sheikh MA, Althouse AD, Freese KE, et al. USA Endometrial Cancer Projections to 2030: should we be concerned? Future Oncology. 2014;10(16):2561-2568. doi: 10.2217/fon.14.192.

2. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecologic Oncology. 2009;114(1):121-127. doi: 10.1016/j.ygyno.2009.03.039.

3. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Obesity and Age at Diagnosis of Endometrial Cancer. Obstetrics & Gynecology. 2014;124(2, PART 1):300-306. doi: 10.1097/aog.0000000000000381.

4. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity. 2008;32(9):1431-1437. doi: 10.1038/ijo.2008.102.

5. Byers T, Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocrine Related Cancer. 2015;22(3):R125-R134. doi: 10.1530/erc-14-0580.

6. Берштейн Л.М. Гетерогенность ожирения и рак: потенциальная роль бурой жировой ткани. // Вопросы онкологии. – 2012. –Т. 58. – №4. – С.464-472. [Bershtein LM. Geterogennost' ozhireniya i rak: potentsial'naya rol' buroy zhirovoy tkani. Voprosy onkologii. 2012; 58 (4): 464-472. (in Russ.)].

7. Berstein LM. Insulinemia, heterogeneity of obesity and the risk of different types of endometrial cancer: existing evidence. Expert Review of Endocrinology & Metabolism. 2016;11(1):51-64. doi: 10.1586/17446651.2016.1128325.

8. Andres R. Effect of obesity on total mortality. Int J Obes. 1980;4(4):381-386.

9. Sims EAH. Characterization of the syndromes of obesity, diabetes mellitus and obesity. Baltimore, London: Williams& Wilkins.1982.

10. Karelis AD, St-Pierre DH, Conus F, et al. Metabolic and Body Composition Factors in Subgroups of Obesity: What Do We Know? The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2569-2575. doi: 10.1210/jc.2004-0165.

11. van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocrine Disorders. 2014;14(1). doi: 10.1186/1472-6823-14-9.

12. Романцова Т.И., Островская Е.В. Метаболически здоровое ожирение: дефиниции, протективные факторы, клиническая значимость. // Альманах клинической медицины. – 2015. – № Спецвыпуск 1. – С. 75–86. [Romantsova TI, Ostrovskaja EV. Metabolicheski zdorovoe ozhirenie: definitsii, protektivnye faktory, klinicheskaya znachimost'. Al'manakh klinicheskoy meditsiny 2015;1S:75-86. (in Russ.)].

13. Bell JA, Hamer M, Sabia S, et al. The Natural Course of Healthy Obesity Over 20 Years. Journal of the American College of Cardiology. 2015;65(1):101-102. doi: 10.1016/j.jacc.2014.09.077.

14. Rothman KJ. BMI-related errors in the measurement of obesity. International Journal of Obesity. 2008;32:S56-S59. doi: 10.1038/ijo.2008.87.

15. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015;129(7):872-880. doi: 10.1016/j.puhe.2015.04.017.

16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. doi: 10.1007/bf00280883.

17. Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2013;45(1):28-36. doi: 10.1007/s12020-013-9973-3.

18. Kavalkova P, Touskova V, Roubicek T, et al. Serum Preadipocyte Factor-1 Concentrations in Females with Obesity and Type 2 Diabetes Mellitus: The Influence of Very Low Calorie Diet, Acute Hyperinsulinemia, and Fenofibrate Treatment. Hormone and Metabolic Research. 2013;45(11):820-826. doi: 10.1055/s-0033-1353210.

19. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin Is Expressed and Produced by Human Muscle and Adipose Tissue in Association With Obesity and Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism. 2013;98(4):E769-E778. doi: 10.1210/jc.2012-2749.

20. Shoukry A, Shalaby SM, El-Arabi Bdeer S, et al. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life. 2016;68(7):544-556. doi: 10.1002/iub.1511.

21. Provatopoulou X, Georgiou GP, Kalogera E, et al. Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics. BMC Cancer. 2015;15(1). doi: 10.1186/s12885-015-1898-1.

22. Szydło B, Kiczmer P, Świętochowska E, Ostrowska Z. Role of omentin and chemerin in metabolic syndrome and tumor diseases. Postępy Higieny i Medycyny Doświadczalnej. 2016;70:844-849. doi: 10.5604/17322693.1214137.

23. Esposito K, Chiodini P, Capuano A, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44(3):634-647. doi: 10.1007/s12020-013-9939-5.

24. Argilés JM, Orpí M, Busquets S, López-Soriano FJ. Myostatin: more than just a regulator of muscle mass. Drug Discovery Today. 2012;17(13-14):702-709. doi: 10.1016/j.drudis.2012.02.001.

25. Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. British Journal of Nutrition. 2015;114(07):999-1012. doi: 10.1017/s0007114515002093.

26. Setiawan VW, Yang HP, Pike MC, et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal of Clinical Oncology. 2013;31(20):2607-2618. doi: 10.1200/jco.2012.48.2596.

27. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. American Journal of Obstetrics and Gynecology. 2011;205(6):518-525. doi: 10.1016/j.ajog.2011.05.042.